James Barrow (Trades, Portfolio) is executive director of Dallas-based investment firm Barrow, Hanley, Mewhinney & Strauss, the lead portfolio manager for the Vanguard Windsor II and Selected Value Funds. For the 10-year period ended 3/31/2010, the Selected Value Funds averaged 9.33% a year, while the market had negative returns. The firm invest in equities with below-market price-to-earnings ratios, below-market price-to-book ratios, and above-market dividend yields.
Pfizer (PFE) is one of James Barrow (Trades, Portfolio)'s top ten holdings. As of the last quarter, his firm held 62.76 million shares of the company. Pfizer Inc. is a research-based, global biopharmaceutical company. The company is involved in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. Pfizer's EPS forecast for the current year is $2.09 and next year is $2.23. According to the consensus estimates, its top line is expected to decline 6.10% in the current year and grow 1% next year. It is trading at a forward P/E of 15.44. Out of 20 analysts covering the company, 14 are positive and have buy recommendations, four have hold ratings, two have sell recommedations. Continue Reading »